> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Mylan and Revance Therapeutics Partner on Botox Biosimilar
- URL: https://www.fdaweb.com/mylan-and-revance-therapeutics-partner-on-botox-biosimilar/
- Published: 2018-03-01T12:00:00.000Z
- Updated: 2026-09-14T23:26:24.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5140884

Mylan and Revance Therapeutics have entered into a collaboration to develop a proposed biosimilar to Botox (onabotulinumtoxinA). The collaboration includes a $25 million upfront payment to Revance, with contingent milestone payments upon achievement of additional clinical, regulatory and sales targets. Botox is indicated for treating bladder conditions, migraine headaches, muscle stiffness, and wrinkles on the face, among other uses.